论文部分内容阅读
目的:探究低分子肝素应用在肾病综合征高凝状态患者治疗中的临床效果。方法:将2015年3月-2016年3月期间我院收治的86例急性脑栓塞肾病综合征高凝状态患者分为两组:对照组和试验组,每组43例。对照组采用泼尼松治疗,试验组采用低分子肝素治疗。结果:对照组的临床总有有效率为76.74%,试验组患者的临床总有效率为93.02%,试验组患者的临床疗效明显的比对照组高,差异具有统计学意义(P<0.05)。结论:低分子肝素应用在肾病综合征高凝状态患者治疗中疗效确切,可明显降低肾病综合征并发的高凝状态,对于减少并发症发生率以及提升患者生存质量等方面具有着至关重要的作用,在临床中值得广泛推广应用。
Objective: To investigate the clinical effect of low molecular weight heparin in the treatment of patients with hypercoagulable state of nephrotic syndrome. Methods: Eighty-six patients with hypercoagulable state of acute cerebral embolism nephrotic syndrome admitted in our hospital from March 2015 to March 2016 were divided into two groups: control group and trial group, with 43 cases in each group. The control group was treated with prednisone, and the experimental group was treated with low molecular weight heparin. Results: The total effective rate of the control group was 76.74%. The total effective rate of the experimental group was 93.02%. The clinical efficacy of the experimental group was significantly higher than that of the control group (P <0.05). Conclusion: The application of low molecular weight heparin in the treatment of patients with nephrotic syndrome hypercoagulable state curative effect is exact, can significantly reduce nephrotic syndrome complicated with hypercoagulable state, to reduce the incidence of complications and improve the quality of life of patients has the crucial Role in the clinical should be widely applied.